WALTHAM, Mass.--(BUSINESS WIRE)-- Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that Katrine Bosley, Avila’s Chief Executive Officer, is scheduled to present a corporate update at the 10th Annual Needham Healthcare Conference, on Wednesday, April 6, 2011 at 1:40 p.m. ET at the New York Palace Hotel.
About Avila Therapeutics™, Inc.
Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes. This approach, called “protein silencing”, cannot be achieved through traditional chemistry techniques. The company’s product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on cancer, viral infection and autoimmune disease. Avila’s most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. For additional information, please visit http://www.avilatx.com.
The Yates Network
Gina Nugent, 617-460-3579
KEYWORDS: United States North America Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical General Health